Mode
Text Size
Log in / Sign up
N/A N=32 Treatment

Efficacy Of Bupropion For Attention Deficit Hyperactivity Disorder (ADHD) In Adults

Attention Deficit Hyperactivity Disorder (ADHD) · Substance Use Disorder (SUD)

Enrolled (actual)
32
Serious AEs
0.0%
Results posted
Feb 2011
Primary outcome: Primary: Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS) Score — 19.4 Units on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Bupropion SR (Drug)
Age
Adult · 18+ yrs
Sex
All
Sponsor
Massachusetts General Hospital
Primary completion
Jul 2001

Outcome Measures

OutcomeResultp-value
PRIMARY
Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS) Score
19.4
PRIMARY
Self-reported Weekly Substance Use
18
SECONDARY
Clinical Global Impressions (CGI) Scale of Substance Use Disorder (SUD) Severity
3.1
SECONDARY
Clinical Global Impressions (CGI) Scale of ADHD Severity
3.8
SECONDARY
Hamilton Anxiety Scale (HAM-A)
4.5
SECONDARY
Hamilton Depression Scale (HAM-D)
4.5
SECONDARY
Beck Depression Inventory (BDI)
3.7

Summary

The investigators propose to conduct an open study to evaluate the efficacy and tolerability of Bupropion SR using clinically relevant doses in ADHD adults with a recent history of or current substance use disorders. We hypothesize that Bupropion SR will be effective in treating ADHD in this population.

Eligibility Criteria

Inclusion Criteria

  • Male and female outpatients 18 years old or older, up to 60 years old.
  • Patients with the diagnosis of Attention Deficit Hyperactivity Disorder (ADHD), by DSM-IV, as manifested in clinical evaluation and confirmed by structured interview.
  • Patients within the past 6 months known to abuse or to be dependent on alcohol or any drug (nicotine addiction not included)

Exclusion Criteria

  • Any clinically unstable medical condition
  • Clinically significant abnormal baseline laboratory values
  • Mental retardation (I.Q. <75) or Organic brain disorders
  • Seizure disorder
  • Patients with a history or an eating disorder including anorexia or bulimia nervosa
  • Pregnant or nursing females
  • Patients with current bipolar disorder
  • Psychotic disorder of any type
  • Patients on psychotropics known to treat ADHD (i.e. stimulants, tricyclics)
  • Patients receiving psychotherapy known to treat ADHD (i.e. cognitive or cognitive/behavioral psychotherapy)
  • Patients demonstrating active withdrawal from substance abuse
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01270555). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search